scPharmaceuticals (NASDAQ:SCPH) Earns “Buy” Rating from HC Wainwright

scPharmaceuticals (NASDAQ:SCPH)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They currently have a $18.00 target price on the stock.

scPharmaceuticals Stock Down 0.3 %

Shares of NASDAQ SCPH opened at $3.00 on Thursday. scPharmaceuticals has a 12-month low of $2.75 and a 12-month high of $5.65. The company has a market cap of $150.12 million, a P/E ratio of -1.58 and a beta of 0.40. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The stock has a fifty day moving average price of $3.27 and a 200 day moving average price of $3.78.

scPharmaceuticals (NASDAQ:SCPH) last announced its quarterly earnings results on Wednesday, March 19th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.05. scPharmaceuticals had a negative return on equity of 244.93% and a negative net margin of 264.60%. The firm had revenue of $12.15 million during the quarter, compared to the consensus estimate of $12.08 million. Research analysts anticipate that scPharmaceuticals will post -1.53 EPS for the current fiscal year.

Institutional Trading of scPharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans grew its stake in shares of scPharmaceuticals by 1.4% during the third quarter. Thrivent Financial for Lutherans now owns 1,048,938 shares of the company’s stock valued at $4,783,000 after acquiring an additional 14,866 shares in the last quarter. King Luther Capital Management Corp grew its stake in shares of scPharmaceuticals by 0.9% during the third quarter. King Luther Capital Management Corp now owns 2,225,790 shares of the company’s stock valued at $10,150,000 after acquiring an additional 20,650 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of scPharmaceuticals during the third quarter valued at about $57,000. BNP Paribas Financial Markets grew its stake in shares of scPharmaceuticals by 116.9% during the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after acquiring an additional 3,101 shares in the last quarter. Finally, Rubric Capital Management LP grew its stake in shares of scPharmaceuticals by 35.5% during the third quarter. Rubric Capital Management LP now owns 4,775,000 shares of the company’s stock valued at $21,774,000 after acquiring an additional 1,250,000 shares in the last quarter. 89.52% of the stock is currently owned by institutional investors and hedge funds.

scPharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.